Comparative Pharmacology
Head-to-head clinical analysis: FLUONID versus METI DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUONID versus METI DERM.
FLUONID vs METI-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
METI-DERM contains methylprednisolone aceponate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and prostaglandin synthesis, thereby reducing inflammation, pruritus, and vasodilation.
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
Apply a thin film topically to affected area once or twice daily.
None Documented
None Documented
3.5 hours; prolonged to 18–24 hours in severe hepatic impairment.
Terminal elimination half-life: 6–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min).
Renal 70% as unchanged drug, biliary/fecal 30% as metabolites.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~35% as metabolites and unchanged drug; minor respiratory elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid